14 үр дүн
Stroke is classically characterized as a neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause, including cerebral infarction, intracerebral haemorrhage, and subarachnoid haemorrhage, and is a major cause of disability and death worldwide. Stroke
Background:
Early mobilization is a component of the ABCDE bundle (Awaken from sedation; Breathe independently from ventilator; Choice of sedation; Delirium management; Early mobilization), an interdisciplinary, patient-centered strategy to facilitate evidence-based practices in intensive care unit
Introduction Stroke can be defined as an abrupt loss of brain function that is caused by decreased cerebral blood flow.
Stroke can occur at all stages of life, but presentation is variable depending on age, involved artery, and underlying risk factors.
Younger children usually present with non
Methods:
Design: The DIRECT ANGIO trial is a French academic, investigator-initiated, multicenter, controlled, open-label, blinded endpoint, two-arm randomized, clinical trial to compare the effectiveness and safety of direct angio-suite admission versus the standard radiological or emergency
Space-occupying, malignant middle cerebral artery (M-MCA) infarctions are still one of the most devastating forms of ischemic stroke, with a mortality of up to 80% in untreated patients.
Actually, M-MCA infarctions constitute between 1% to 10% of all supratentorial ischemic strokes, with a yearly
About 112 eligible participants will be identified from primary care by a member of the research practitioner or member of research/clinical teams (patient identification sites) outpatient clinics (stroke clinics, neurology clinics, geriatric clinics, neurosurgical clinics) and from acute stroke
Space-occupying, malignant middle cerebral artery (M-MCA) infarctions are still one of the most devastating forms of ischemic stroke, with a mortality of up to 80% in untreated patients.The term M-MCA is referred to a severe middle cerebral artery (MCA) syndrome with typical clinical symptoms
The investigators will follow the STROBE guidelines to perform this prospective observational study. All patient demographics, co-morbidities and surgical details that are relevant to calculate the EuroSCORE will be recorded using our institutional automatic anesthesia record system. Laboratory
1.0 Background
While atrial fibrillation (AF) is the most common sustained cardiac arrhythmia requiring therapy, it is also associated with increased risk of stroke, heart failure, myocardial infarction, dementia, and death. The number of Americans affected with AF is expected to surge to nearly 16
Background Stroke is the third leading cause of death in most western countries, and the major cause of adult disability leaving two thirds of stroke survivors struggling with moderate to severe disability. Stroke affects approximately 15 million people worldwide each year.
Up to 90% of all strokes
Design: This Phase II efficacy trial is a multi-centre, open label, single arm, non-comparative design, administering a single dose of CTX cells 2 to 3 months post-ischaemic stroke with follow-up over 12 months. The trial will be overseen by an independent DSMB. The DSMB will adjudicate at
The investigators will begin to test the hypothesis that rTMS will be tolerated and will result in improved hand strength and mobility when compared with sham stimulation.
Aim 1: To determine whether 1 Hz rTMS applied to the hemisphere opposite the infarct (contralesional or healthy hemisphere) is
1. Introduction:
Renal function and cardiac surgery
Impaired kidney function is a well known complication to cardiac surgery and is observed in up to 30% of the patients, depending on the definition of acute kidney injury (AKI). The precise pathophysiological mechanisms are unknown, it is, however,
Design: The trial is an open label, single administration, ascending dose, single site trial using CTX neural stem cells with 24-month patient monitoring following treatment.
Pre-treatment selection of patients : Males aged ≥60 years with unilateral ischaemic stroke affecting sub-cortical white